Injectable Semaglutide Under $150/Month: The Complete Verified List

The sub-$150 price point for injectable compounded semaglutide was rare 18 months ago. In early 2025, most providers clustered between $199 and $299/month. By mid-2026, competition and API cost reductions have pushed starting prices into the $99 to $149 range at several providers — creating a budget tier that didn't previously exist.

But "under $150" doesn't mean "all the same." The providers in this price range differ significantly in what's included in that monthly rate, what gets billed separately, and how the price changes as you titrate. This guide breaks down each sub-$150 option with the context you need to evaluate whether the advertised price is the actual price.

What "Starting Price" Actually Means

Every price in this guide is the monthly cost at the lowest available dose tier (typically 0.25 mg/week semaglutide). This is the price you see in ads and on enrollment pages. It is not:

• The price at your maintenance dose (usually higher)
• The total cost including one-time enrollment or consultation fees
• A guaranteed rate that stays fixed as you titrate
• The price after a promotional period expires

When we say a provider is "under $150/month," we mean the starting monthly medication cost. Any additional fees are noted separately.

The Sub-$150 Landscape

The compounded semaglutide market under $150/month is real but comes with important context. Providers at this price point typically fall into three categories:

Category 1: Permanently Priced Under $150 at Starting Dose

Some providers have set their starting-dose pricing at $129 to $149 as a permanent (non-promotional) rate. These providers plan to retain patients through titration, where higher doses generate higher per-month revenue. The under-$150 starting price is a patient acquisition strategy — get patients in the door at an accessible price, then earn margin at maintenance doses.

This model works well for patients who may not titrate to the highest doses, or who plan to maintain at a moderate dose level where the per-month cost stays reasonable.

Category 2: Promotional Pricing With Expiration

Other providers offer sub-$150 rates as limited-time promotions — first-month specials, seasonal discounts, or introductory offers that revert to higher pricing after 1 to 3 months. The month-1 price is under $150; the month-4 price may be $199 or higher.

These promotions are legitimate savings for your first month, but they don't represent the ongoing cost of treatment. Always ask: "What will my rate be after the introductory period ends?"

Category 3: Unbundled Pricing

The most important distinction. Some providers achieve a sub-$150 monthly medication price by billing other services separately: consultation fees ($49–$99), lab work ($50–$150), shipping ($15–$25), or platform/membership fees ($10–$30/month). The medication itself is under $150, but the total monthly cost — once all line items are added — may be $175 to $250.

This isn't necessarily deceptive — some patients prefer to see itemized costs rather than a bundled rate. But it means the apples-to-apples comparison requires looking at total cost, not just the medication line item.

What to Verify at Any Sub-$150 Provider

• Pharmacy accreditation: At lower price points, the temptation to cut corners on pharmacy quality increases. Verify the compounding pharmacy's license, accreditation status (PCAB, ACHC), and any FDA warning letter history.
• Total first-month cost: Add up every line item — medication, consultation, enrollment, shipping, supplies, lab work. What's the actual total?
• Dose-tier pricing: What does month 4 cost at 1.0 mg? What does month 8 cost at 2.4 mg? The starting price is one data point in a multi-month trajectory.
• Cancellation terms: Budget providers sometimes offset lower medication pricing with stricter commitment requirements or cancellation fees.
• Cold-chain shipping: Temperature-controlled shipping costs money. Providers at the lowest price points may use standard shipping without cold packs — acceptable in winter, risky in summer.

The "Too Cheap" Red Line

Legitimate cost reduction can come from operational efficiency, high patient volume (spreading fixed costs across more prescriptions), or API purchasing power. Illegitimate cost reduction comes from using non-pharmaceutical-grade ingredients, skipping sterility testing, operating without proper licensure, or employing non-compliant shipping practices.

The price floor for legitimately compounded, properly tested, cold-chain-shipped injectable semaglutide — accounting for API cost, pharmacy labor, testing, packaging, and shipping — is estimated at approximately $60 to $80 per month at current market rates. Providers priced at or below this floor are either operating at a loss (venture-funded subsidy), cutting quality corners, or both.

Frequently Asked Questions